Research Library — Eli Lilly | Reta Compare
49 research articles in Eli Lilly. Page 1 of 2.
Articles
- Overview of Eli Lilly's Lawsuits Against Compounded Tirzepatide
- Eli Lilly v. Hims & Hers Health
- Eli Lilly v. Ro (Roman) and Affiliated Pharmacies
- Eli Lilly Sues Multiple Compounding Pharmacies in 2025
- Why Lilly Uses the Lanham Act Instead of the FDCA
- Trademark Infringement Claims in Lilly's Compounding Suits
- Lilly's False Advertising Claims Against Telehealth Operators
- State Consumer Protection Claims in Compounded GLP-1 Suits
- Preliminary Injunctions Granted in Lilly's Favor in 2025
- Lilly's Testimony Before Congress on Compounded Peptides
- Eli Lilly v. Empower Pharmacy
- Eli Lilly's Stance on 503A vs 503B Compounded Products
- Damages and Disgorgement in Lilly's Compounded Tirzepatide Cases
- Eli Lilly Cease and Desist Letters to Compounders
- Eli Lilly v. Strive Pharmacy
- Eli Lilly v. Revive Pharmacy
- Eli Lilly v. Henry Meds
- Eli Lilly v. Mochi Health
- Eli Lilly v. Found
- Eli Lilly v. Sesame Care
- Eli Lilly v. Red Rock Pharmacy
- Lilly's Settlement Patterns in Compounded Tirzepatide Cases
- Defending Against a Lilly Lanham Act Claim: Key Arguments
- Eli Lilly and the Lilly Patents Portfolio on Tirzepatide
- LillyDirect and the Litigation Strategy